Ultra-wealthy investors shift portfolios amid Iran-driven energy shock and global economic fragmentation, increasing allocations to commodities and defensive assets.
Revolution Medicines (NASDAQ: RVMD) surged over 41 percent after Phase 3 results showed significant survival improvements in pancreatic cancer treatment.